NPI: 1417947490 · LAS VEGAS, NV 89106 · Psychiatric Hospital Unit · NPI assigned 10/21/2005
Authorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
| Authorized Official | FILTON, STEVE (CFO, SENIOR VP) |
| NPI Enumeration Date | 10/21/2005 |
Other providers sharing the same authorized official: FILTON, STEVE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 187,723 | $2.72M |
| 2019 | 398,862 | $7.41M |
| 2020 | 350,669 | $6.51M |
| 2021 | 377,144 | $7.32M |
| 2022 | 321,810 | $7.19M |
| 2023 | 364,312 | $8.05M |
| 2024 | 320,921 | $7.83M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 82,161 | 66,387 | $8.97M |
| G0378 | Hospital observation service, per hour | 44,823 | 29,830 | $4.96M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 38,581 | 34,012 | $3.58M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12,603 | 10,565 | $3.20M |
| 70450 | Computed tomography, head or brain; without contrast material | 20,537 | 17,384 | $2.17M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 34,431 | 28,255 | $1.81M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 8,568 | 7,268 | $1.69M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2,722 | 2,321 | $1.34M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 4,572 | 3,844 | $1.27M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 51,198 | 39,932 | $1.13M |
| 96361 | Intravenous infusion, hydration; each additional hour | 45,300 | 32,858 | $1.05M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 56,110 | 43,610 | $882K |
| 96375 | Therapeutic injection; each additional sequential IV push | 53,837 | 37,161 | $865K |
| 72125 | Computed tomography, cervical spine; without contrast material | 4,477 | 3,904 | $683K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4,763 | 3,889 | $634K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 10,878 | 4,435 | $508K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 17,684 | 13,906 | $477K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 38,958 | 22,943 | $459K |
| 96376 | 28,272 | 14,206 | $374K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 11,888 | 10,468 | $353K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 130,944 | 83,747 | $353K |
| 72131 | 2,075 | 1,800 | $314K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 68,583 | 51,238 | $304K |
| 80053 | Comprehensive metabolic panel | 71,188 | 56,202 | $298K |
| 84484 | 70,656 | 35,683 | $288K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 21,148 | 17,225 | $257K |
| J2785 | Injection, regadenoson, 0.1 mg | 2,594 | 2,205 | $257K |
| 70496 | 847 | 706 | $254K | |
| 71045 | Radiologic examination, chest; single view | 47,192 | 37,512 | $253K |
| 11045 | 1,514 | 688 | $252K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 8,667 | 5,262 | $239K |
| 0450 | Emergency room services | 5,248 | 4,557 | $235K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6,974 | 6,231 | $234K |
| 70498 | 829 | 694 | $231K | |
| 95819 | 1,422 | 1,035 | $203K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3,267 | 3,057 | $200K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 2,712 | 2,316 | $199K |
| 36415 | Collection of venous blood by venipuncture | 154,698 | 90,186 | $199K |
| 97162 | 6,398 | 5,270 | $194K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 946 | 747 | $179K |
| 80048 | Basic metabolic panel (calcium, ionized) | 48,266 | 35,418 | $168K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5,292 | 4,398 | $166K |
| 93970 | 2,957 | 2,436 | $155K | |
| 84702 | 25,776 | 21,571 | $151K | |
| 70486 | 1,432 | 1,328 | $150K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2,657 | 2,310 | $149K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 11,195 | 6,097 | $144K |
| 76830 | Ultrasound, transvaginal | 1,935 | 1,708 | $134K |
| 83880 | 13,697 | 10,943 | $128K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 2,912 | 2,551 | $127K |
| 97535 | Self-care/home management training, each 15 minutes | 9,139 | 5,488 | $124K |
| 93971 | 3,087 | 2,667 | $119K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 453 | 321 | $115K |
| 71046 | Radiologic examination, chest; 2 views | 10,132 | 8,864 | $115K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 35,692 | 21,992 | $93K |
| 83605 | 25,305 | 17,971 | $93K | |
| 83690 | 34,230 | 27,407 | $91K | |
| 71250 | 896 | 720 | $89K | |
| 83735 | 46,372 | 24,324 | $81K | |
| 97166 | 2,638 | 2,234 | $81K | |
| 76801 | 1,280 | 1,126 | $76K | |
| 90715 | 2,192 | 1,988 | $73K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2,963 | 2,737 | $68K |
| 87040 | 16,056 | 8,409 | $65K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 9,007 | 7,235 | $64K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2,206 | 1,781 | $61K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,034 | 2,223 | $57K |
| 81001 | 45,702 | 37,743 | $52K | |
| 73564 | 3,034 | 2,714 | $50K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 295 | 261 | $50K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 2,196 | 1,712 | $50K |
| 85730 | 30,766 | 23,602 | $50K | |
| 87641 | 7,640 | 5,948 | $50K | |
| J3370 | Injection, vancomycin hcl, 500 mg | 5,541 | 2,921 | $49K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 17,140 | 14,395 | $49K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 289 | 223 | $49K |
| 96367 | 3,929 | 2,947 | $45K | |
| 93017 | 2,713 | 2,309 | $43K | |
| 82550 | 19,190 | 14,474 | $43K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2,561 | 2,258 | $43K |
| 85610 | 36,170 | 27,642 | $40K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2,516 | 2,136 | $39K |
| 97161 | 1,305 | 1,048 | $39K | |
| 84443 | Thyroid stimulating hormone (TSH) | 10,544 | 8,561 | $39K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2,502 | 2,124 | $39K |
| 97116 | 4,590 | 2,893 | $38K | |
| 73630 | 2,769 | 2,476 | $36K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 14,603 | 9,853 | $35K |
| 81025 | 13,801 | 11,937 | $35K | |
| 94060 | 878 | 815 | $33K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1,144 | 781 | $33K |
| 82962 | 44,720 | 14,323 | $31K | |
| 73610 | 2,151 | 1,933 | $31K | |
| 85379 | 8,374 | 7,079 | $31K | |
| 97163 | 1,133 | 923 | $30K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3,065 | 1,754 | $30K |
| 73130 | 1,869 | 1,688 | $30K | |
| 80069 | 22,625 | 10,870 | $29K | |
| 80076 | 10,491 | 7,750 | $29K | |
| 10060 | 412 | 381 | $27K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 488 | 431 | $27K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2,181 | 1,946 | $27K |
| 92610 | 1,113 | 898 | $27K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 474 | 231 | $27K |
| 87186 | 8,793 | 6,106 | $26K | |
| 74022 | 1,386 | 1,182 | $26K | |
| 73030 | 2,140 | 1,903 | $25K | |
| A9585 | Injection, gadobutrol, 0.1 ml | 1,272 | 953 | $24K |
| 0250 | 1,496 | 547 | $24K | |
| 72100 | 1,871 | 1,652 | $24K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 4,103 | 2,995 | $23K |
| 80074 | 2,592 | 2,103 | $23K | |
| 84145 | 3,912 | 2,890 | $22K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2,162 | 1,944 | $22K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 5,804 | 3,945 | $22K |
| 93880 | 324 | 266 | $21K | |
| 94729 | 858 | 796 | $21K | |
| 82803 | 4,415 | 3,046 | $21K | |
| 47563 | 14 | 13 | $20K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 643 | 509 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 44,021 | 31,499 | $20K |
| 73110 | 1,068 | 972 | $20K | |
| 97165 | 810 | 622 | $19K | |
| 85027 | 9,133 | 5,790 | $19K | |
| Z7502 | 521 | 445 | $19K | |
| J2358 | Injection, olanzapine, long-acting, 1 mg | 1,104 | 819 | $19K |
| 70491 | 121 | 109 | $19K | |
| 0762 | 18 | 13 | $19K | |
| 80061 | Lipid panel | 4,571 | 3,815 | $18K |
| 0270 | 1,638 | 944 | $18K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 748 | 623 | $18K |
| J1644 | Injection, heparin sodium, per 1000 units | 17,798 | 7,384 | $18K |
| J1953 | Injection, levetiracetam, 10 mg | 2,599 | 1,455 | $17K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 3,311 | 1,833 | $17K |
| 97167 | 542 | 449 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 6,692 | 5,645 | $17K |
| 97602 | 1,298 | 981 | $16K | |
| 73502 | 1,282 | 1,103 | $15K | |
| 82140 | 4,094 | 3,069 | $15K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 270 | 193 | $15K |
| 81003 | 18,212 | 15,118 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 11,387 | 9,415 | $13K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 11,003 | 9,071 | $13K |
| 74174 | 31 | 26 | $13K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 11,674 | 9,225 | $13K |
| 94726 | 481 | 453 | $12K | |
| C1781 | Mesh (implantable) | 145 | 131 | $12K |
| J1170 | Injection, hydromorphone, up to 4 mg | 7,675 | 4,980 | $12K |
| J1650 | Injection, enoxaparin sodium, 10 mg | 4,582 | 2,040 | $12K |
| 94660 | 119 | 55 | $12K | |
| 87077 | 2,901 | 2,187 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 613 | 572 | $11K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 237 | 226 | $11K |
| J0780 | Injection, prochlorperazine, up to 10 mg | 1,839 | 1,496 | $10K |
| 86140 | 6,856 | 5,078 | $10K | |
| 96368 | 1,226 | 1,017 | $9K | |
| J3490 | Unclassified drugs | 709 | 447 | $9K |
| 76775 | 656 | 543 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 12,225 | 10,098 | $9K |
| 74018 | 1,115 | 828 | $9K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 4,871 | 3,632 | $8K |
| 71101 | 513 | 465 | $8K | |
| 82607 | 2,339 | 1,899 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2,888 | 2,377 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1,781 | 1,460 | $8K |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 1,928 | 907 | $8K |
| J1790 | Injection, droperidol, up to 5 mg | 642 | 554 | $8K |
| J1815 | Injection, insulin, per 5 units | 1,397 | 902 | $7K |
| 87070 | 3,900 | 2,927 | $7K | |
| 84439 | 5,478 | 4,353 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | 11,478 | 8,455 | $6K |
| C9113 | Injection, pantoprazole sodium, per vial | 5,336 | 2,813 | $6K |
| 36600 | 2,256 | 1,683 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 940 | 465 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 9,344 | 6,734 | $6K |
| 82330 | 1,564 | 1,258 | $6K | |
| 84481 | 3,711 | 2,907 | $6K | |
| J0456 | Injection, azithromycin, 500 mg | 2,905 | 1,851 | $6K |
| 87205 | 5,361 | 3,877 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 7,501 | 5,488 | $6K |
| 73080 | 369 | 340 | $6K | |
| 73590 | 545 | 492 | $6K | |
| J3480 | Injection, potassium chloride, per 2 meq | 2,300 | 1,523 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 69 | 62 | $6K |
| J2800 | Injection, methocarbamol, up to 10 ml | 1,187 | 933 | $5K |
| 72128 | 78 | 68 | $5K | |
| 99199 | Unlisted special service, procedure or report | 112 | 66 | $5K |
| 86901 | 6,428 | 5,297 | $5K | |
| 82010 | 1,811 | 1,490 | $5K | |
| 82746 | 1,699 | 1,374 | $5K | |
| 86900 | 6,257 | 5,135 | $5K | |
| J2704 | Injection, propofol, 10 mg | 9,072 | 7,340 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | 5,017 | 3,737 | $5K |
| 11043 | 29 | 17 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 633 | 521 | $5K |
| 97597 | 716 | 482 | $5K | |
| 94664 | 704 | 494 | $5K | |
| 99070 | 610 | 238 | $5K | |
| 82728 | 2,282 | 1,747 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 3,127 | 2,212 | $4K |
| 73700 | 31 | 25 | $4K | |
| J1940 | Injection, furosemide, up to 20 mg | 4,097 | 2,001 | $4K |
| 86850 | 5,209 | 4,213 | $4K | |
| 72040 | 339 | 287 | $4K | |
| 84132 | 3,731 | 2,871 | $4K | |
| 36430 | 327 | 234 | $4K | |
| J3411 | Injection, thiamine hcl, 100 mg | 977 | 628 | $4K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 635 | 308 | $4K |
| 94644 | 235 | 194 | $4K | |
| 94727 | 291 | 264 | $4K | |
| J1630 | Injection, haloperidol, up to 5 mg | 2,529 | 1,891 | $4K |
| 84100 | 4,683 | 3,530 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | 100 | 25 | $4K |
| 87486 | 571 | 445 | $3K | |
| 87581 | 571 | 445 | $3K | |
| G0008 | Administration of influenza virus vaccine | 692 | 549 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 563 | 437 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 231 | 198 | $3K |
| J2359 | Injection, olanzapine, 0.5 mg | 266 | 167 | $3K |
| 86923 | 469 | 360 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 5,548 | 4,528 | $3K |
| 80202 | 486 | 268 | $3K | |
| 87210 | 1,498 | 1,239 | $3K | |
| 86780 | 434 | 375 | $3K | |
| 83550 | 2,311 | 1,821 | $3K | |
| 85652 | 3,688 | 2,825 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 364 | 256 | $3K |
| 76870 | 92 | 81 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 112 | 88 | $2K |
| 87075 | 739 | 608 | $2K | |
| 83540 | 2,296 | 1,827 | $2K | |
| 91200 | 116 | 109 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 121 | 110 | $2K |
| 73090 | 152 | 141 | $2K | |
| 90686 | 690 | 555 | $2K | |
| 87563 | 125 | 120 | $2K | |
| 84295 | 1,559 | 1,241 | $2K | |
| 85014 | 3,081 | 2,133 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 404 | 310 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 1,424 | 1,258 | $1K |
| 82805 | 138 | 125 | $1K | |
| 64721 | 13 | 12 | $1K | |
| C1769 | Guide wire | 1,092 | 821 | $1K |
| 82570 | 1,660 | 1,109 | $1K | |
| 85046 | 1,427 | 1,052 | $1K | |
| 12001 | 42 | 42 | $1K | |
| 85018 | 3,135 | 2,172 | $1K | |
| Z7610 | 113 | 31 | $1K | |
| 76377 | 33 | 24 | $1K | |
| 29125 | 69 | 53 | $1K | |
| 87449 | 523 | 439 | $1K | |
| 72072 | 85 | 68 | $994.45 | |
| 87081 | 778 | 570 | $979.20 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 216 | 196 | $917.77 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 6,329 | 5,105 | $904.76 |
| 83615 | 897 | 640 | $856.61 | |
| P9046 | Infusion, albumin (human), 25%, 20 ml | 35 | 13 | $845.35 |
| 87276 | 380 | 333 | $817.12 | |
| 84300 | 1,449 | 1,086 | $791.99 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 55 | 26 | $784.02 |
| 83930 | 863 | 643 | $780.64 | |
| 87275 | 381 | 333 | $777.62 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 821 | 553 | $674.60 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 280 | 177 | $619.91 |
| 80164 | 232 | 142 | $600.20 | |
| 87184 | 328 | 271 | $581.22 | |
| 85520 | 124 | 55 | $579.54 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 996 | 829 | $517.16 |
| 87631 | 206 | 181 | $506.77 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 274 | 220 | $468.17 |
| 99152 | 58 | 51 | $457.78 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 70 | 51 | $409.44 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 1,160 | 654 | $327.77 |
| 72170 | 48 | 39 | $299.92 | |
| J3360 | Injection, diazepam, up to 5 mg | 39 | 28 | $258.94 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 21 | 18 | $251.38 |
| 73140 | 14 | 14 | $227.73 | |
| 84550 | 168 | 147 | $223.70 | |
| 82947 | 107 | 92 | $217.34 | |
| J1836 | Injection, metronidazole, 10 mg | 355 | 178 | $217.14 |
| 82542 | 53 | 39 | $195.91 | |
| 83935 | 267 | 193 | $191.73 | |
| 73552 | 12 | 12 | $155.02 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 190 | 151 | $149.20 |
| 87899 | 205 | 169 | $148.15 | |
| 83970 | 19 | 12 | $118.55 | |
| 85384 | 184 | 114 | $110.01 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 21 | 15 | $107.23 |
| 84540 | 406 | 302 | $100.69 | |
| A4217 | Sterile water/saline, 500 ml | 14 | 13 | $100.43 |
| A9270 | Non-covered item or service | 49,871 | 7,001 | $100.30 |
| 84156 | 157 | 109 | $92.50 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 98 | 72 | $87.97 |
| 84133 | 177 | 122 | $76.65 | |
| 82248 | 53 | 40 | $72.63 | |
| 82436 | 154 | 105 | $68.86 | |
| 87430 | 76 | 70 | $68.31 | |
| 82565 | 29 | 24 | $64.29 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 930 | 631 | $57.79 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 28 | 15 | $34.85 |
| 83010 | 38 | 26 | $34.32 | |
| 84155 | 16 | 14 | $23.28 | |
| 84520 | 14 | 12 | $21.60 | |
| 83520 | 20 | 12 | $17.66 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 106 | 101 | $11.03 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | 12 | 12 | $9.38 |
| 89051 | 17 | 12 | $7.52 | |
| 87181 | 15 | 12 | $7.02 | |
| 85007 | 102 | 48 | $2.59 | |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 100 | 83 | $0.01 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 58 | 54 | $0.01 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 57 | 53 | $0.01 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 403 | 285 | $0.01 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 403 | 285 | $0.01 |
| C1729 | Catheter, drainage | 45 | 39 | $0.00 |
| 0353U | 712 | 668 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 432 | 295 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 435 | 297 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 295 | 225 | $0.00 |
| 88312 | 39 | 25 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 33 | 30 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 51 | 38 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 13 | 13 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 12 | 12 | $0.00 |